CLINICOHISTOPATHOLOGICAL CHARACTERISTICS OF PROSTATE LESIONS AT RUMAH SAKIT PENDIDIKAN PROF. DR. CHAIRUDDIN PANUSUNAN LUBIS MEDAN, 2023-2024
KARAKTERISTIK KLINIKOHISTOPATOLOGI LESI PROSTAT DI RUMAH SAKIT PENDIDIKAN PROF. DR. CHAIRUDDIN PANUSUNAN LUBIS MEDAN, 2023–2024
Abstract
Prostatic enlargement is a global health problem among older men, caused by non-neoplastic or neoplastic lesions and commonly presenting as lower urinary tract symptoms. Benign Prostatic Hyperplasia (BPH) is the leading non-neoplastic etiology, whereas Acinar Prostatic Carcinoma (APC) is the most common malignant neoplasm. High-Grade Prostatic Intraepithelial Neoplasia (HGPIN), a precursor lesion, and Atypical Small Acinar Proliferation (ASAP), a suspicious atypical acinar proliferation, are critical differential diagnoses and pitfalls influencing management and prognosis. Using total sampling, this retrospective cross-sectional study characterized clinicohistopathological features of prostatic lesions in patients undergoing prostate core needle biopsy and/or transurethral resection of the prostate at Rumah Sakit Pendidikan Prof. dr. Chairuddin Panusunan Lubis Medan, from January 2023 to June 2024. Histopathological evaluation used hematoxylin and eosin staining. Forty-three specimens were analyzed descriptively: 33 (76.74%) were BPH and 10 (23.26%) were APC; neither ASAP nor HGPIN was identified. Benign and malignant lesions occurred most frequently among patients aged 60–69 years; the youngest were aged 50–59 years. Ultrasonographic diagnoses agreed with histopathology in 83.33% of BPH cases and 66.67% of APC cases. BPH specimens predominantly showed papillary infolding and cystic atrophy, corpora amylacea as the principal intraluminal secretion, and squamous metaplasia as a distinctive finding. APC specimens predominantly showed tufting, cribriform, and micropapillary architectures; blue mucin and crystalloids as intraluminal secretions; and signet-ring cell morphology as a distinctive finding. Benign lesions showed papillary infolding and cystic atrophy, with intraluminal corpora amylacea. Malignant lesions showed tufting, cribriform and micropapillary patterns, with intraluminal blue mucin and crystalloids.
References
Speakman MJ, Cheng X, Kirby RS, Novara G, Wolff JM. The Global, Regional, and National Burden of Benign Prostatic Hyperplasia in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet Heal Longev. 2022;3(11):e754–e776. doi:10.1016/S2666-7568(22)00213-6
Ng M, Lynch J. Benign Prostatic Hyperplasia. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK558920/. Accessed January 26, 2026.
Chen X, Li Y, Zhang Q, Wang Y, Liu Z. Global, Regional, and National Burden of Benign Prostatic Hyperplasia, 1990–2019: A Systematic Analysis. Sci Rep. 2025;15:90229. doi:10.1038/s41598-025-90229-3
Ye Z, Wang Y, Wang S, Hu H, Zhang X. Global Burden of Benign Prostatic Hyperplasia in Males: An Analysis Based on the Global Burden of Disease Study 2019. BMC Urol. 2024;24:158. doi:10.1186/s12894-024-01582-w
Ikatan Ahli Urologi Indonesia. Panduan Praktik Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia). 2021. Available from: https://iaui.or.id/uploads/guidelines/2021_P
PK_PEMBESARAN_PROSTAT_JINAK_BPH.pdf. Accessed January 26, 2026.
Raharjo RA, Mochtar CA, Umbas R. Diagnosis and Treatment Patterns of Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Asia. Ther Adv Urol. 2016;8(6):371-383. doi:10.1177/1756287216665893
Guo Z, Zhu S, Wu J, Liu X, Xu T. Prevalence and Risk Factors for Incidental Prostate Cancer in Patients After Transurethral Resection of the Prostate with Negative Results on Prostate Biopsy: A Retrospective Study. Int Brazilian J Urol. 2022;48(6):1015-1026. https://pmc.ncbi.nlm.nih.gov/articles/PMC8902422/. Accessed January 26, 2026.
Janjua TK, Iqbal MS, Rasheed H, Akhter S, Iqbal Z. Incidental Finding of Prostate Cancer in Transurethral Resection of Prostate (TURP) Specimens: A Retrospective Analysis from a Tertiary Care Hospital in Pakistan. Pan Afr Med J. 2021;39:20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8348362/. Accessed January 26, 2026.
Xu Y, Che W, Zhang Q, Wang J, Gao Y. The Benign Mimickers of Prostatic Acinar Adenocarcinoma. Transl Androl Urol. 2016;5(1):23-32. doi:10.3978/j.issn.2223-4683.2016.01.02
Tsampoukas G, Zafeiriou Z, Aggelakis S, Karyotis I, Deliveliotis C. Atypical Small Acinar Proliferation and Its Significance in Pathological Reports in Modern Urological Times. J Clin Med. 2021;11(2):248. doi:10.3390/jcm11020248
Leone A, Gershman B, Rotker K, Butler C, Fantasia J, Miller A. Atypical Small Acinar Proliferation (ASAP): Is a Repeat Biopsy Necessary? A Multi-Institutional Review. Prostate Cancer Prostatic Dis. 2016;19(1):68-71. doi:10.1038/pcan.2015.53
Iczkowski KA, DeMarzo AM, Agarwal N, et al. International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1: The Prostate. Am J Surg Pathol. 2025;49(12):e33–e45. doi:10.1097/PAS.0000000000002430
Surintrspanont J, Klotz L, Epstein JI, Netto GJ, Magi-Galluzzi C. Prostate Pathology: What is New in the 2022 WHO Classification. Cancers (Basel). 2023;15(14):3621. doi:10.3390/cancers15143621
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
Wang Z, Lu S, He Y, Wang Y, Wang L, Du L. Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries from 2000 to 2019. Front Public Heal. 2022;10:811044. doi:10.3389/fpubh.2022.811044
Global Cancer Observatory. United States of America Fact Sheet (GLOBOCAN 2022). 2024. https://gco.iarc.who.int/media/globocan/factsheets/populations/840-united-states-of-america-fact-sheet.pdf. Accessed January 26, 2026.
Global Cancer Observatory. Europe Fact Sheet (GLOBOCAN 2022). 2024. https://gco.iarc.who.int/media/globocan/factsheets/populations/908-europe-fact-sheet.pdf. Accessed January 26, 2026.
Eala MA, Dee EC, Jacomina LE, et al. Prostate Cancer in Southeast Asia: An Analysis of 2022 Incidence and Mortality Data. Int J Radiat Oncol Biol Phys. 2024;120(2 Suppl):e528. doi:10.1016/j.ijrobp.2024.07.1170
Kristiana T, Dewi IGASM, Maker LPII, Saputra H, Sriwidyani NP, Muliarta IM. Loss of Phosphatase and Tensin Homologue (PTEN) Expression Associated with Higher Risk Grade Group Gleason Prostate Adenocarcinoma in Sanglah Hospital Denpasar. Indones J Cancer. 2019;13(4):127-132. doi:10.33371/ijoc.v13i4.680
Wei H, Zhu C, Huang Q, et al. Global, Regional, and National Burden of Benign Prostatic Hyperplasia from 1990 to 2021 and Projection to 2035. BMC Urol. 2025;25(1):34. doi:10.1186/s12894-025-01715-9
Lim KB. Epidemiology of Clinical Benign Prostatic Hyperplasia. Asian J Urol. 2017;4(3):148-151. https://pmc.ncbi.nlm.nih.gov/articles/PMC5717991/. Accessed January 26, 2026.
Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11-19. doi:10.1097/JU.0000000000003698
Gravas S, Cornu JN, Gacci M, et al. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), Including Benign Prostatic Obstruction (BPO): EAU Guidelines 2023. Eur Urol. 2023;84(1):64-85. https://www.europeanurology.com/article/S0302-2838(23)02731-8/fulltext. Accessed January 26, 2026.
Vuichoud C, Loughlin KR. Benign Prostatic Hyperplasia: Epidemiology, Economics and Evaluation. Can J Urol. 2015;22(Suppl 1):1-6. https://www.canjurol.com/html/free-articles/JUV22I5S1F_06_DrLoughlin.pdf. Accessed January 26, 2026.
National Cancer Institute. Cancer Stat Facts: Prostate Cancer. 2026. https://seer.cancer.gov/statfacts/html/prost.html. Accessed January 26, 2026.
Centers for Disease Control and Prevention. Prostate Cancer Incidence. 2026. https://www.cdc.gov/united-states-cancer-statistics/publications/prostate-cancer.html. Accessed January 26, 2026.
de Vos II, Remmers S, Hogenhout R, Roobol MJ, Group ERS. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol. 2024;85(1):74-81. doi:10.1016/j.eururo.2023.10.011
European Association of Urology. EAU Guidelines on Prostate Cancer: Classification and Staging Systems (Risk Groups; PSA Cut-offs). 2026. https://uroweb.org/guidelines/prostate-cancer/chapter/classification-and-staging-systems. Accessed January 26, 2026.
Luining WI, Brouwer OR, DeJong J, Van Leeuwen PJ, Donswijk ML, Meijer D. The Probability of Metastases Within Different Prostate-Specific Antigen Levels in Patients Undergoing PSMA PET/CT for Primary Staging of Prostate Cancer. Eur Urol Open Sci. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10829602/. Accessed January 26, 2026.
National Cancer Institute. Prostate-Specific Antigen (PSA) Test. 2026. https://www.cancer.gov/types/prostate/psa-fact-sheet. Accessed January 26, 2026.
American Urological Association, Society of Urologic Oncology. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023). 2023. https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer. Accessed January 26, 2026.
American Urological Association, Society of Urologic Oncology. Advanced Prostate Cancer: AUA/SUO Guideline. 2026. https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer. Accessed January 26, 2026.
David MK, Leslie SW. Prostate-Specific Antigen. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK557495/. Accessed January 26, 2026.
European Association of Urology. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026. https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation. Accessed January 26, 2026.
Descotes JL. Diagnosis of Prostate Cancer. Asian J Urol. 2019;6(2):129-136. doi:10.1016/j.ajur.2018.11.007
Shareef S, Joshi A. Effectiveness of Transabdominal Ultrasonography in Assessing Benign versus Malignant Nature of Prostatomegaly. Int J Res Med Sci. 2019;7(6):2297-2301. https://www.msjonline.org/index.php/ijrms/article/download/6488/4819/25814. Accessed January 26, 2026.
Jawli A, Huang Z, Almansour H, Ahmed HU, Sidhu HS. The Performance of Different Parametric Ultrasounds in Prostate Cancer Diagnosis: Correlation with Radical Prostatectomy Specimens. Diagnostics. 2024;14(8).
McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. Cancer Manag Res. 2020;12:5225-5241.
Humphrey PA. Histopathology of Prostate Cancer. Cold Spring Harb Perspect Med. 2017;7(10):a030411. doi:10.1101/cshperspect.a030411
Guo CC, Czerniak B. Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors. J Clin Transl Pathol. 2023;3(1):26-34. doi:10.14218/JCTP.2022.00029
Magi-Galluzzi C. Prostate Cancer: Diagnostic Criteria and Role of Immunohistochemistry. Mod Pathol. 2018;31(Suppl 1):12-21. doi:10.1038/modpathol.2017.139
DuPre NC, Wang A, Nelson HH, et al. Corpora Amylacea in Prostatectomy Tissue and Associations with Molecular, Histological, and Lifestyle Factors. Prostate. 2018;78(15):1172-1180. doi:10.1002/pros.23692
Copyright (c) 2027 Lidya Imelda Laksmi, Causa Trisna Mariedina, Betty, Joko S Lukitoa, Arie Widiansyah Hasibuan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
